Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia.


Journal

Experimental hematology
ISSN: 1873-2399
Titre abrégé: Exp Hematol
Pays: Netherlands
ID NLM: 0402313

Informations de publication

Date de publication:
05 2019
Historique:
received: 20 12 2018
revised: 11 02 2019
accepted: 24 02 2019
pubmed: 3 3 2019
medline: 19 2 2020
entrez: 3 3 2019
Statut: ppublish

Résumé

The TEL-AML1 fusion gene, generated by the t(12;21) chromosome translocation, arises in a progenitor/stem cell and could induce clonal expansion of a persistent preleukemic B-cell clone which, on acquisition of secondary alterations, may turn into full-blown leukemia. During infections, deregulated cytokine signaling, including transforming growth factor β (TGF-β), can further accelerate this process by creating a protumoral bone marrow (BM) microenvironment. Here, we show that activin A, a member of the TGF-β family induced under inflammatory conditions, inhibits the proliferation of normal progenitor B cells but not that of preleukemic TEL-AML1-positive clones, thereby providing a selective advantage to the latter. Finally, we find that activin A inhibits BM-derived mesenchymal stromal cell-mediated secretion of CXCL12, a major chemoattractant in the BM compartment, thereby contributing to shape a leukemia-promoting environment. Overall, our findings indicate that activin A, in concert with TGF-β, could play an important role in the creation of a pro-oncogenic BM microenvironment and provide novel mechanistic insights into TEL-AML1-associated leukemogenesis.

Identifiants

pubmed: 30825516
pii: S0301-472X(19)30079-7
doi: 10.1016/j.exphem.2019.02.006
pii:
doi:

Substances chimiques

CXCL12 protein, human 0
Chemokine CXCL12 0
Core Binding Factor Alpha 2 Subunit 0
Oncogene Proteins, Fusion 0
TEL-AML1 fusion protein 0
activin A 0
Activins 104625-48-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-12.e4

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL103726
Pays : United States

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Federica Portale (F)

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.

Linda Beneforti (L)

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.

Alessandra Fallati (A)

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.

Andrea Biondi (A)

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy; Clinica Pediatrica Ospedale S. Gerardo, Fondazione MBBM, University of Milano-Bicocca, Monza, Italy.

Chiara Palmi (C)

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.

Giovanni Cazzaniga (G)

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.

Erica Dander (E)

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.

Giovanna D'Amico (G)

Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy. Electronic address: giovanna.damico@asst-monza.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH